Cyclosporine

Generic Name: Cyclosporine

Brand Names: Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis

Drug Type: Small Molecule

Chemical Formula: C_₆₂H_₁₁₁N_₁₁O_₁₂

CAS Number: 59865-13-3

Unique Ingredient Identifier: 83HN0GTJ6D

Background: Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...

Indication: Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...

Associated Conditions: Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production

Associated Therapies: -

Clinical Trials

CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly

Phase 4

Not yet recruiting

Conditions: Aplastic Anemia

Interventions: Drug: Ciclosporin
Drug: Avatrombopag
Drug: Anti-Human Thymocyte Immunoglobulin, Rabbit

First Posted Date: 2023-08-18

Last Posted Date: 2023-08-18

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 60

Registration Number: NCT05996393

Locations: 🇨🇳
Peking union medical college hospital, Beijing, China

A Clinical Study of MIL62 in Primary Membranous Nephropathy

Phase 3

Recruiting

Conditions: Primary Membranous Nephropathy

Interventions: Drug: MIL62
Drug: Cyclosporine

First Posted Date: 2023-05-17

Last Posted Date: 2024-11-20

Lead Sponsor: Beijing Mabworks Biotech Co., Ltd.

Target Recruit Count: 150

Registration Number: NCT05862233

Locations: 🇨🇳
Peking University First Hospital, Beijing, China

HU007 in Patients With Dry Eye Syndrome

Phase 3

Completed

Conditions: Dry Eye Disease

Interventions: Drug: HU007
Drug: Moisview Eye drop
Drug: Restasis

First Posted Date: 2023-02-24

Last Posted Date: 2024-05-13

Lead Sponsor: Huons Co., Ltd.

Target Recruit Count: 328

Registration Number: NCT05743764

Locations: 🇰🇷
Gyeongsang National University Hospital, Jinju, Korea, Republic of

Optimization of Cyclosporin in Atopic Dermatitis Through Multiomic Predictive Models of Treatment Response

Phase 4

Recruiting

Conditions: Atopic Dermatitis

Interventions: Other: Follow-up of Cyclospoin treatment already started
Drug: Cyclosporin A

First Posted Date: 2023-01-20

Last Posted Date: 2023-04-28

Lead Sponsor: Instituto de Investigación Hospital Universitario La Paz

Target Recruit Count: 100

Registration Number: NCT05692843

Locations: 🇪🇸
Hospital La Paz, Madrid, Spain

Effect of Cyclosporine and Remote Ischemic Preconditioning in Reperfusion Ischemia Injury on Tetralogy Fallot Patients With Correction Surgery

Not Applicable

Completed

Conditions: Myocardial Injury
Cardiac Surgery

Interventions: Drug: Placebo
Drug: Cyclosporin
Procedure: remote ischemic preconditioning

First Posted Date: 2023-01-20

Last Posted Date: 2023-01-20

Lead Sponsor: Indonesia University

Target Recruit Count: 40

Registration Number: NCT05691764

Locations: 🇮🇩
Indonesia University, Jakarta, DKI Jakarta, Indonesia

Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy

Recruiting

Conditions: Dermatitis, Atopic

First Posted Date: 2023-01-06

Last Posted Date: 2023-01-06

Lead Sponsor: Fundación Academia Española de Dermatología

Target Recruit Count: 2500

Registration Number: NCT05674695

Locations: 🇪🇸
Hospital Universitario de la Princesa, Madrid, Spain
🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain
🇪🇸
Hospital del Mar IMIM, Barcelona, Spain

and more 6 locations

A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Phase 3

Recruiting

Conditions: Severe Aplastic Anemia

Interventions: Drug: cyclosporine
Procedure: Matched Unrelated Donor Hematopoetic Stem Cell Transplant
Drug: horse anti-thymocyte globulin (ATG)
Procedure: Immunosuppressive Therapy (IST)
Drug: rabbit anti-thymocyte globulin (ATG)
Drug: Methotrexate
Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: low-dose total body irradiation (TBI)

First Posted Date: 2022-10-31

Last Posted Date: 2024-11-08

Lead Sponsor: Boston Children's Hospital

Target Recruit Count: 234

Registration Number: NCT05600426

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Arkansas, Little Rock, Arkansas, United States

and more 46 locations